Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)

Trial Profile

Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 26 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top